Radiation beads for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a treatment that delivers tiny radioactive beads directly to liver tumors through a tube. It is for people with one or a few small liver tumors that cannot be removed with surgery or destroyed with heat or cold. The goal is to shrink or control the tumors with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer confirmed by a biopsy or imaging scan.
- You have either one tumor between 2 and 5 cm, or two to three tumors each 3 cm or smaller.
- You have not had any prior treatment for these tumors.
- You are not a candidate for surgery or thermal ablation (using heat or cold to destroy tumors).
- You are 22 years or older.
- Your liver function is adequate, with bilirubin ≤ 3.0 mg/dL, AST and ALT ≤ 5 times the upper limit of normal, and GFR > 30 ml/min.
- Your liver disease severity is within limits (Child-Pugh score ≤ B7 and ALBI score 1-2).
- You have not received systemic therapy (whole-body cancer treatment) for liver cancer.
- You are not pregnant and agree to stop breastfeeding if treated.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how patients with liver cancer (HCC) respond to a treatment called SIR-Spheres, which are tiny radioactive beads placed in the liver. It is for people who received this treatment in 2023 or early 2024 and were checked for tumor response within six months after treatment.
This trial tests combining radiation therapy (radioembolization) with surgery to remove part of the liver for people with a single large liver tumor (over 8 cm) that hasn't spread. The goal is to see if this approach can treat the tumor effectively.
This trial tests a treatment called yttrium-90 radioembolization (tiny radioactive beads delivered to the liver) for people with liver cancer that has already been treated before. The goal is to see if it can help control the tumor when other treatments haven't been enough.
This Phase 2 trial tests TheraSphere® (a Y-90 radiation treatment delivered to the liver) combined with standard systemic therapy in people with high-risk hepatocellular carcinoma (HCC). It aims to shrink tumors and improve outcomes for people whose liver cancer is at higher risk to worsen.
This trial tests a new combination for liver cancer that cannot be surgically removed yet. It uses tiny radioactive beads (yttrium-90) to deliver radiation directly to the tumor, along with immunotherapy drugs and a targeted therapy to shrink the tumor, with the hope that it can later be surgically removed.
This trial tests a treatment called Y-90 radioembolization (SIRT) for people with liver cancer that is too large to be removed surgically. The treatment delivers tiny radioactive beads directly to the tumor through the liver's blood supply, which may shrink the tumor and improve outcomes.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.